Characterization of asthma endotypes: implications for therapy

Annals of Allergy, Asthma and Immunology

Volumn 117, Issue 2, 2016, Pages 121-125

  Stokes, Jeffrey R ^a   Casale, Thomas B ^b  

^a CREIGHTON UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENRALIZUMAB; DUPILUMAB; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR ALPHA; LEBRIKIZUMAB; LIGELIZUMAB; MEPOLIZUMAB; OMALIZUMAB; PITRAKINRA; PLACEBO; PROSTAGLANDIN D2; QUILIZUMAB; RESLIZUMAB; TRALOKINUMAB; ANTIASTHMATIC AGENT; AUTACOID; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; CYTOKINE;

APOPTOSIS; ASTHMA; DISEASE EXACERBATION; DRUG TARGETING; EOSINOPHIL; FORCED EXPIRATORY VOLUME; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUTROPHIL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SPUTUM; TH2 CELL; BLOOD; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL PRODUCTS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; LYMPHOCYTE COUNT; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE; SIGNAL TRANSDUCTION; TH2 CELLS;

EID: 84991721600     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2016.05.016     Document Type: Review

References (37)

1. [1] Lockey, R.F., Asthma phenotypes: an approach to the diagnosis and treatment of asthma. J Allergy Clin Immunol Pract 2 (2014), 682–685.
2. [2] Barnes, P.J., Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol 136 (2015), 531–545.
3. [3] Nair, P., Gaga, M., Zervas, E., et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 42 (2012), 1097–1103.
4. [4] Nowak, R.M., Parker, J.M., Silverman, R.A., et al. A randomized trial of benralizumab, an anti interleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med 33 (2015), 14–20.
5. [5] Flood-Page, P., Swenson, C., Faiferman, I., et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176 (2007), 1062–1071.
6. [6] Haldar, P., Brightling, C.E., Hargadon, B., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 (2009), 973–984.
7. [7] Pavord, I.D., Korn, S., Howarth, P., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo controlled trial. Lancet 380 (2012), 651–659.
8. [8] Liu, Y., Zhang, S., Li, D.W., Jiang, S.J., Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo controlled trials. PLoS One, 8, 2013, e59872 [erratum PLoS One. 2013;8(6)].
9. [9] Ortega, H.G., Liu, M.C., Pavord, I.D., et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
10. [10] Nair, P., Pizzichini, M.M., Kjarsgaard, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360 (2009), 985–993.
11. [11] Bel, E.H., Wenzel, S.E., Thompson, P.J., et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371 (2014), 1189–1197.
12. [12] Ortega, H., Li, H., Suruki, R., Albers, F., Gordon, D., Yancey, S., Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc 11 (2014), 1011–1017.
13. [13] Haldar, P., Brightling, C.E., Singapuri, A., et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol 133 (2014), 921–923.
14. [14] Castro, M., Mathur, S., Hargreave, F., et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 184 (2011), 1125–1132.
15. [15] Corren, J., Weinstein, S., Janka, L., Zangrilli, J., Garin, M., Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. [published online ahead of print March 24, 216] Chest, 2016 http://dx.doi.org/10.1016/j.chest.2016.03.018.
16. [16] Castro, M., Zangrilli, J., Wechsler, M.E., et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3 (2015), 355–366.
17. [17] Lim, H.F., Nair, P., Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma. Expert Rev Respir Med 9 (2015), 135–142.
18. [18] Laviolette, M., Gossage, D.L., Gauvreau, G., et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132 (2013), 1086–1096.e5 [erratum J Allergy Clin Immunol. 2014;133:1232].
19. [19] Castro, M., Wenzel, S.E., Bleecker, E.R., et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2 (2014), 879–890.
20. [20] Izuhara, K., Conway, S.J., Moore, B.B., et al. Roles of periostin in respiratory disorders. Am J Respir Crit Care Med 193 (2016), 949–956.
21. [21] Corren, J., Lemanske, R.F., Hanania, N.A., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 365 (2011), 1088–1098.
22. [22] Noonan, M., Korenblat, P., Mosesova, S., et al. Dose ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 132 (2013), 567–574.
23. [23] Hanania, N.A., Noonan, M., Corren, J., et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70 (2015), 748–756.
24. [24] Investor update. http://www.roche.com/investors/updates/inv-update-2016-02-29.htm. Published February 29, 2016. Accessed March 28, 2016.
25. [25] Piper, E., Brightling, C., Niven, R., et al. A phase II placebo controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 41 (2013), 330–338.
26. [26] Brightling, C.E., Chanez, P., Leigh, R., et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 3 (2015), 692–701.
27. [27] Wenzel, S., Ford, L., Pearlman, D., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368 (2013), 2455–2466.
28. [28] Positive phase 2b data for treatment of asthma with dupilumab. http://www.rtmagazine.com/2015/05/positive-phase-2b-data-asthma-dupilumab/. Published May 21, 2015. Accessed March 28, 2016.
29. [29] Wenzel, S., Wilbraham, D., Fuller, R., Getz, E.B., Longphre, M., Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370 (2007), 1422–1431.
30. [30] Slager, R.E., Otulana, B.A., Hawkins, G.A., et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti–IL-4 receptor α antagonist. J Allergy Clin Immunol 130 (2012), 516–522.e4.
31. [31] Gauvreau, G.M., Harris, J.M., Boulet, L.P., et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med, 6, 2014, 243ra85.
32. [32] Harris, J.M., Maciuca, R., Bradley, S., et al. Efficacy and safety of quilizumab in adults with allergic asthma inadequately controlled on inhaled corticosteroids and a second controller (COSTA Study) C101. Allergic airway inflammation and hyperresponsiveness: novel mechanism and therapy. Am J Respir Crit Care Med, 191, 2015, A5168.
33. [33] Arm, J.P., Bottoli, I., Skerjanec, A., et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 44 (2014), 1371–1385.
34. [34] Humbert, M., Busse, W., Hanania, N.A., et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2 (2014), 525–536.e1.
35. [35] Hanania, N.A., Wenzel, S., Rosén, K., et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187 (2013), 804–811.
36. [36] Busse, W., Spector, S., Rosén, K., Wang, Y., Alpan, O., High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol 132 (2013), 485–486.e11.
37. [37] Pettipher, R., Hunter, M.G., Perkins, C.M., et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy 69 (2014), 1223–1232.